PTC/SB/08s (08-03.)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

US Person and Technical Control (1995), no persons are required to regard to a calculation of information of these of control varieties and information of the control varieties and control varieties and control varieties.

Application Number

Fing Date

2006-02-27

A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

pplication Number			
iling Date		2006-02-27	
irst Named Inventor	Hiroy	ruki NAKAHIRA	
rt Unit			
xaminer Name			
ttomey Docket Numb	er	Q93343	Π

	U.S.PATENTS					Remove					
Examiner Initial*	Cite No	Patent Number	Kind Code ¹			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines wher Relevant Passages or Rele Figures Appear			
	1										
If you wis	h to a	dd additional U.S. Pater							Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant iment	Releva		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code ²	Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or (or Relevant	
	1	0268420	EP		A1	2002-09-06	Boehringer Ingelhe Pharma KG	im			
	2	0224698	EΡ		A	2002-03-28	Schering Corp.				
	3	200443429	JP		A	2004-02-12	Eisai Co., Ltd.				
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add										

	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)					
		Filing Date		2006-02-27		
		First Named Inventor Hiroy		yuki NAKAHIRA		
		Art Unit			_	
		Examiner Name				
l		Attorney Docket Number		Q93343		
					_	
	NON-	PATENT LITERATURE	DOC	JMENTS Remove	_	

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

T5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Application Number

publisher, city and/or country where published.

Evaminer Cite

English language translation is attached.

Initials* No.

1							
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner Signature	Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a							

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at year USPTO_GOV or MPEP 901.04. 2 Enter office that issued the document, by the hor-letter code (WIPO Standard ST 3). 2 For Japanese patent document, be included not be year of the migror of the Emparer may proced the serial number of the patent country. Afford of colonnets by the approprise spreads are activated to the Construct drue WIPO Standard ST 1/6 (possite.) Explaint is to piece a chark may be referred.

	Application Number			
UFORMATION DIGGI COURT	Filing Date		2006-02-27	
	First Named Inventor Hiroy		yuki NAKAHIRA	
	Art Unit			
(Examiner Name			
	Attorney Docket Numb	er	Q93343	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) First Named Inventor Art Unit Examiner Name	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

√ None

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to tile (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to set in four to complete, including gathering, preparing and submitting the complete four complete to the complete this form and/or suggestions for reducing this burden, about be sent to the Cheld Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commance, P.O. 80s 1450, Alexandris, V.A.2511-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandris, VA.2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested to the process and/or examine your submission, which may related the process and/or examine your submission, which may related the process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.